--- title: "Vera Therapeutics: Buy Rating Reiterated on Strong Atacicept Outlook and Launch Readiness; $73 Price Target Maintained" type: "News" locale: "en" url: "https://longbridge.com/en/news/285662461.md" description: "Analyst Ritu Baral from TD Cowen has reiterated a Buy rating on Vera Therapeutics, maintaining a price target of $73. The positive outlook is driven by the strong regulatory and clinical positioning of atacicept for IgA nephropathy, with a priority-review PDUFA date set for July 7. The company is preparing for launch with a focused nephrology sales force and a solid cash position, ensuring operational stability. LifeSci Capital also supports the stock with a Buy rating and a $90 price target." datetime: "2026-05-08T04:07:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285662461.md) - [en](https://longbridge.com/en/news/285662461.md) - [zh-HK](https://longbridge.com/zh-HK/news/285662461.md) --- # Vera Therapeutics: Buy Rating Reiterated on Strong Atacicept Outlook and Launch Readiness; $73 Price Target Maintained Analyst Ritu Baral from TD Cowen maintained a Buy rating on Vera Therapeutics and keeping the price target at $73.00. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Ritu Baral has given his Buy rating due to a combination of factors, foremost among them the strong regulatory and clinical positioning of atacicept in IgA nephropathy. The drug has secured a priority-review PDUFA date of July 7, and the BLA is backed by Phase 3 data showing a meaningful and statistically significant reduction in proteinuria versus placebo, supporting expectations for a relatively clean approval and competitive labeling. Ritu Baral’s rating is based on Vera’s commercial readiness and financial runway, which together de-risk the launch execution. Management is building a focused nephrology sales force to cover a majority of U.S. nephrologists, and pricing is likely to be comparable to a high benchmark set by a recently launched competitor, implying attractive revenue potential. In addition, a solid cash position provides operating runway beyond the expected approval and launch, allowing the company to advance further data readouts and lifecycle expansion without near-term financing pressure. The price target is unchanged at $73, reflecting the favorable risk‑reward profile. According to TipRanks, Baral is a top 100 analyst with an average return of 47.8% and a 55.67% success rate. Baral covers the Healthcare sector, focusing on stocks such as COMPASS Pathways, Praxis Precision Medicines, and ACADIA Pharmaceuticals. In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $90.00 price target. ### Related Stocks - [VERA.US](https://longbridge.com/en/quote/VERA.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [TD.US](https://longbridge.com/en/quote/TD.US.md) - [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md) - [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md) - [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md) ## Related News & Research - [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)